时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
PURPOSE: Older and vulnerable patients with metastatic non-small-cell lung cancer (NSCLC) are underrepresented in clinical trials, and evidence guiding treatment intensity remains limited. We investigated whether a modified Cancer and Aging Research Group (mCARG) score could prospectively guide chemotherapy intensity according to estimated toxicity risk. METHODS: In this randomized, open-label phase II study, 201 patients with metastatic NSCLC aged ≥ 70 years and/or Charlson Comorbidity Index (CCI) > 1 and/or ECOG performance status ≥ 2 were stratified by mCARG score. Patients with mCARG ≤ 3 received platinum-doublet chemotherapy (CTX), whereas those with mCARG > 3 received single-agent CTX.…
对本项目的价值
中等价值：属「干预策略与临床转化」方向；干预策略与临床试验栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.2/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：改良 CARG 评分指导老年或脆弱晚期 NSCLC 一线治疗：随机 II 期 DURATION 试验
- 英文标题：Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416).
- 期刊与标识：Clin Lung Cancer · PMID 42966192 · DOI 10.1016/j.cllc.2026.10.004 · EDAT 2026-10-31